Product Information
METHYLPHENIDATE CD 30 MG CAP is a generic product labeled by Lannett Company Inc., priced at $1.7946 per EA under NDC 00527458137. Its NADAC has been published 392 times since Apr 3, 2019.
FDA first approved this application on Apr 3, 2001. Its Orange Book therapeutic-equivalence code is AB2 — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
30 mg/1
Manufacturer
Lannett Company Inc.NDC
00527458137
Classification
Generic
Dosage Form
CAPSULE, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
METHYLPHENIDATE HYDROCHLORIDEApproval Type
Authorized Generic (NDA)
FDA Application
NDA021259FDA Approved
4/3/2001
TE Code
AB2
On Market Since
7/22/2003
Pharmacological Classes
Price Statistics
The NADAC for METHYLPHENIDATE CD 30 MG CAP has been published 392 times since Apr 3, 2019, and over the history we have for it it has declined 41.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.7946 per EA |
|---|---|
| All-time high | $3.0564 (May 15, 2019) |
| All-time low | $0.9240 (Jul 17, 2024) |
| 52-week high | $1.9151 |
| 52-week low | $1.7332 |
| Median price | $1.5684 |
| Average price | $1.7057 |
| Largest weekly change | +58.7% (Jun 19, 2024) |
| Weeks tracked | 392 |
| Tracking since | Apr 3, 2019 |
Generic Alternatives
The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Lannett Company Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
methylphenidate hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Central Nervous System Stimulant class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of METHYLPHENIDATE CD 30 MG CAP?
The current National Average Drug Acquisition Cost (NADAC) for METHYLPHENIDATE CD 30 MG CAP, manufactured by Lannett Company Inc., is $1.7946 per EA (NDC 00527458137), effective Sep 30, 2026.
How has the price of METHYLPHENIDATE CD 30 MG CAP changed over time?
Over the history we have for it, the NADAC for METHYLPHENIDATE CD 30 MG CAP has declined 41.3%. It has been tracked across 392 weekly CMS publications since Apr 3, 2019.
What are the highest and lowest recorded NADAC prices for METHYLPHENIDATE CD 30 MG CAP?
Since Apr 3, 2019, the NADAC for METHYLPHENIDATE CD 30 MG CAP has ranged from a low of $0.9240 (Jul 17, 2024) to a high of $3.0564 (May 15, 2019), with a median of $1.5684 per EA.
Are there cheaper alternatives to METHYLPHENIDATE CD 30 MG CAP?
4 manufacturers publish a NADAC-priced product with the same active ingredient and strength as METHYLPHENIDATE CD 30 MG CAP in a comparable dosage form, but none are currently priced below it.
Who manufactures METHYLPHENIDATE CD 30 MG CAP?
METHYLPHENIDATE CD 30 MG CAP (NDC 00527458137) is labeled by Lannett Company Inc., and CMS classifies it as a generic product.